Bausch Health Cos (NYSE:BHC) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Bausch Health Cos (NYSE:BHC) announced its earnings results on Wednesday. The company reported $1.08 earnings per share for the quarter, missing the consensus estimate of $1.21 by ($0.13), Zacks reports. Bausch Health Cos had a net margin of 3.61% and a negative return on equity of 9,620.34%. The firm had revenue of $2.78 billion during the quarter, compared to analysts’ expectations of $2.71 billion.

Here are the key takeaways from Bausch Health Cos’ conference call:

• Bausch Health reported strong FY2025 operating results — an eleventh consecutive quarter of revenue and adjusted EBITDA growth, more than $1 billion in adjusted operating cash flow, and reduced net debt while improving its debt maturity profile through refinancing actions.
• The company announced a setback in R&D as the RED‑C Phase 3 trials failed to meet primary endpoints; management is reviewing the data to identify any alternative development opportunities.
• Solta completed the December 1, 2025 acquisition of Shibo in China to bring distribution in‑house, which management expects to drive long‑term, double‑digit growth for Solta and restore China as its largest geography.
• XIFAXAN, a key revenue driver, faces headwinds — Q4 included ~<$50M of one‑time Medicaid residuals and management warned of upcoming Medicare rebate and patent/generic risks (potential LOE/generic entry on Jan 1, 2028) that could materially pressure future EBITDA.
• 2026 guidance for Bausch Health (ex Bausch + Lomb) is modestly positive — revenue $5.25–$5.4B and adjusted EBITDA $2.0–$2.1B — while management says it will pursue targeted business development and consider monetizing its Bausch + Lomb stake to unlock shareholder value.

Bausch Health Cos Stock Performance

Shares of NYSE BHC traded down $0.28 during midday trading on Thursday, hitting $5.92. 4,791,723 shares of the company’s stock were exchanged, compared to its average volume of 2,219,490. Bausch Health Cos has a twelve month low of $4.25 and a twelve month high of $8.69. The firm has a market cap of $2.19 billion, a P/E ratio of 6.10 and a beta of 0.42. The stock’s 50 day moving average price is $6.66 and its 200-day moving average price is $6.69. The company has a debt-to-equity ratio of 57.48, a current ratio of 1.30 and a quick ratio of 0.97.

Trending Headlines about Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Reported revenue beat and product momentum — Consolidated Q4 revenue ~ $2.8B (up ~9% year‑over‑year) with growth driven by Salix and Bausch + Lomb businesses; organic trends remain positive. BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Positive Sentiment: FY‑2026 revenue guidance slightly above Street — company provided a $10.6B–$10.9B revenue range and management expects modest (~3%) revenue growth while expanding in China. BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Positive Sentiment: Balance‑sheet actions completed — executed a $1.7B debt exchange and ~$9.6B of refinancing in 2025 to extend maturities, which reduces near‑term refinancing risk. BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Neutral Sentiment: Profitability and cash metrics mixed — Adjusted EBITDA and adjusted cash flow improved (Adjusted EBITDA up, $362M cash from operations in Q4 and $1.2B for FY), but GAAP results included a Q4 net loss. BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Neutral Sentiment: Operational detail available — The investor deck and full earnings‑call transcript provide color on product trends, China expansion and cost posture for 2026. Analysts and investors will parse the call for sustainability of growth. Bausch Health Companies Inc. 2025 Q4 – Results – Earnings Call Presentation
• Positive Sentiment: Product milestone — OraPharma marked 25 years of ARESTIN® (minocycline HCl) use, a niche but durable dental product franchise. Bausch Health’s OraPharma Celebrates 25 Years of ARESTIN
• Negative Sentiment: Q4 EPS missed expectations — GAAP/adjusted EPS came in at $1.08 versus consensus ~$1.21, a notable EPS shortfall that triggered the intraday selloff despite the revenue beat. BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
• Negative Sentiment: Market reaction focused on earnings miss and GAAP loss — outlets reported share weakness after the miss; short‑term investor sentiment is cautious until EPS recovery and margin drivers are clearer. Bausch Health shares fall after significant Q4 earnings miss

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Amundi acquired a new stake in shares of Bausch Health Cos during the fourth quarter worth $103,000. Orion Porfolio Solutions LLC acquired a new position in shares of Bausch Health Cos in the 4th quarter valued at $100,000. Commonwealth Equity Services LLC increased its stake in Bausch Health Cos by 14.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after purchasing an additional 1,812 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in Bausch Health Cos during the 3rd quarter worth about $100,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Bausch Health Cos during the 3rd quarter worth about $95,000. Institutional investors own 78.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BHC. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a research note on Monday, December 29th. Barclays initiated coverage on Bausch Health Cos in a report on Monday, December 8th. They set an “equal weight” rating and a $8.00 target price for the company. Finally, Truist Financial raised their price target on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Five analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.67.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.